Claire Sullivan, MD
Cardiovascular Disease · Cleveland, OHNPI 1558688580
Payments from drug & device makers
Across 107 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$455
- Amgen$376
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$272
- AstraZeneca$185
- Novo Nordisk$124
- Astellas Pharma US Inc$123
- plus $759 from 21 others
What the payments were for
- Food & beverage$2,294100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 19 | $455 |
| Amgen | 20 | $376 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $272 |
| AstraZeneca(2 entities) | 11 | $185 |
| Novo Nordisk | 7 | $124 |
| Astellas Pharma US Inc | 6 | $123 |
| Regeneron Healthcare Solutions, Inc. | 6 | $117 |
| Esperion Therapeutics, Inc. | 4 | $77 |
| Pfizer | 4 | $76 |
| Amarin Pharma, Inc. | 3 | $61 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $58 |
| Lantheus Medical Imaging, Inc. | 2 | $51 |
| Scpharmaceuticals Inc. | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Johnson & Johnson | 2 | $24 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $24 |
| Ionis Pharmaceuticals, Inc. | 1 | $20 |
| ZOLL Circulation Inc | 1 | $20 |
| Boston Scientific | 1 | $20 |
| Abbott | 1 | $19 |
| Bracco Diagnostics Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Merck | 1 | $17 |
| Chiesi USA, Inc. | 1 | $17 |
| Sanofi | 1 | $15 |
| Aroa Biosurgery Incorporated | 1 | $13 |
How this compares
$2,294 in reported general payments places this provider in the 55th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 321 | $206,843 |
| EliquisApixaban | 155 | $138,840 |
| JardianceEmpagliflozin | 55 | $74,424 |
| Praluent PenAlirocumab | 70 | $47,440 |
| OzempicSemaglutide | 42 | $41,330 |
| MounjaroTirzepatide | 32 | $33,928 |
| EntrestoSacubitril/Valsartan | 35 | $32,267 |
| VascepaIcosapent Ethyl | 30 | $22,246 |
| XareltoRivaroxaban | 14 | $16,076 |
| NexletolBempedoic Acid | 14 | $14,087 |
| Dofetilide | 13 | $3,418 |
| Rosuvastatin Calcium | 139 | $1,647 |
| Ezetimibe | 54 | $1,548 |
| Metoprolol Succinate | 112 | $1,477 |
| Nebivolol Hcl | 24 | $1,102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $76 | $138,840155 claims |
| Boehringer IngelheimJardiance | $18 | $74,42455 claims |
| Novo NordiskOzempic | $124 | $41,33042 claims |
| NovartisEntresto | $455 | $32,26735 claims |
| Johnson & JohnsonXarelto | $24 | $16,07614 claims |
| Esperion Therapeutics, Inc.Nexletol | $77 | $14,08714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 827 cardiovascular disease providers in Ohio.
Other cardiovascular disease in Cleveland
- Samir KapadiaCleveland$11.1M
- Steven NissenCleveland$5.3M
- Milind DesaiCleveland$5M
- Abraham LincoffCleveland$3.6M
- Carlos HubbardCleveland$3.1M
- Guilherme AttizzaniCleveland$2.8M
- Wai Hong TangCleveland$2.2M
- Mazen HannaCleveland$1.6M
- Daniel CantillonCleveland$1.3M
- Oussama WazniCleveland$665K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.